✨
AI Summary
- Angiex is developing AGX101, a targeted therapy for solid tumors.
- AGX101 delivers a maytansinoid payload to tumor cells and associated endothelial cells.
- Phase 1 trial data is being evaluated for safety, dose, and efficacy.